Sitemap > Breaking Research > Infectious Diseases
Displaying 101 - 150 of 4290 results
- A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against Staphylococcus aureus infection.
- A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.
- Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.
- RD114-pseudotyped retroviral vectors kill cancer cells by syncytium formation and enhance the cytotoxic effect of the TK/GCV gene therapy strategy.
- Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene.
- Inhibition of respiratory viruses by nasally administered siRNA.
- CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.
- Identification and characterization of an endogenous chemotactic ligand specific for FPRL2.
- Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.
- A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
- Lentiviral transduction of microglial cells.
- Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
- RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis.
- Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy.
- IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.
- Immune and functional role of nitric oxide in a mouse model of respiratory syncytial virus infection.
- In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from Maesa balansae and some chemical derivatives.
- Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans.
- Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients.
- Parotid secretory protein is an HDL-associated protein with anticandidal activity.
- Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin.
- Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
- Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs.
- Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
- New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0.
- Painful peripheral neuropathy associated with voriconazole use.
- Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium.
- Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.
- Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
- Inhibition of endotoxin- and antigen-induced airway inflammation by fudosteine, a mucoactive agent.
- Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
- Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.
- Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1.
- Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.
- Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
- Inhibition of HIV type 1 replication using lentiviral-mediated delivery of mutant tRNA(Lys3)A58U.
- Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
- Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
- Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.
- Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection.
- Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
- Recombinant viral capsids as an efficient vehicle of oligonucleotide delivery into cells.
- Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
- HIV-based vectors and angiogenesis following rabbit hindlimb ischemia.
- Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
- Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus.
- Antileishmanial activity, cytotoxicity and QSAR analysis of synthetic dihydrobenzofuran lignans and related benzofurans.
- CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance.
- RNA polymerase IV directs silencing of endogenous DNA.
- Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 Next >